This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avanir Pharmaceuticals Announces Appointment Of Rohan Palekar As Chief Commercial Officer









ALISO VIEJO, Calif., March 16, 2012 /PRNewswire/ --  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Rohan Palekar to the position of senior vice president and chief commercial officer. Mr. Palekar will be responsible for leading all of the company's commercial activities.

"Rohan has an outstanding track record of success in biopharmaceutical sales and marketing," said Keith A. Katkin, president and CEO of Avanir. "I am delighted that we were able to attract someone of Rohan's caliber to spearhead our global commercial activities. His comprehensive background in healthcare sales and marketing, new product planning and strategic analysis, as well as his leadership capabilities, will be pivotal to the continued commercial success of Avanir."

Mr. Palekar has over 20 years of experience in the biopharmaceutical industry and has worked on significant brands including Remicade® and Stelara®, as well as the investigational therapy MDV3100. Mr. Palekar's most recent commercial leadership role was as chief commercial officer for Medivation, where he was responsible for all commercial activities, CMC & manufacturing and public relations functions. Prior to Medivation, Mr. Palekar spent 16+ years at Johnson & Johnson in various senior commercial and strategic management roles, most recently as a vice president of sales & marketing at Centocor, where he successfully launched two new indications for Remicade.  Prior to that, Mr. Palekar was the worldwide vice president of immunology and held marketing leadership roles at McNeil Consumer and Specialty Pharmaceuticals.  Mr. Palekar earned his MBA from the Amos Tuck School of Business Administration Dartmouth College and his BA/BS in Law and Accounting from the University of Bombay.

"I am excited to be joining the Avanir team and working with this talented group to help make NUEDEXTA available to patients and physicians worldwide," said Rohan Palekar, senior vice president and chief commercial officer of Avanir. "The growth opportunity that lies ahead for Avanir is incredible and I look forward to the chance to positively affect the lives of patients suffering from pseudobulbar affect and other CNS disorders."

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,139.63 +59.49 0.33%
S&P 500 2,124.59 +6.90 0.33%
NASDAQ 5,115.3320 +23.2470 0.46%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs